B&L Retisert DME Trial Results Will Be Presented At ARVO Meeting In May

Preliminary 12-month results from a Phase III clinical trial evaluating Bausch & Lomb's Retisert drug-delivery implant for treatment of diabetic macular edema show a 43.9% serious ocular adverse event rate